ALLMedicine™ Exfoliative Dermatitis Center

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...

Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...

Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...

May 16th, 2016 - Chronic inflammatory peripheral neuropathies are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired fine motor control. Often it is caused by demyelination which is suitab...

Aug 22nd, 2012 - Background : The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. Both are due to the proliferation of a CD4+ T-cell clone in the skin, associated with a blood involvement in Sezary syndrome. Mycosis fungoid...

Nov 13th, 2020 - Bruno Strigini, CEO The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis (SM), SM ...

Jun 28th, 2019 - The Food and Drug Administration has approved bevacizumab-bvzr (Zirabev) – a biosimilar to bevacizumab (Avastin) – for the treatment of five cancers: metastatic colorectal cancer (mCRC); unresectable, locally advanced, recurrent or metastatic non-.

Sep 14th, 2017 - The Food and Drug Administration has approved a biosimilar to bevacizumab (Avastin) for the treatment of certain colorectal, lung, brain, kidney, and cervical cancers. Bevacizumab-awwb is the first biosimilar approved in the United States for the.

Sep 14th, 2017 - The US Food and Drug Administration (FDA) has approved the first biosimilar for use in oncology ― the product is Mvasi (bevacizumab-awwb), from Amgen. It is equivalent to the reference product, Avastin (Genetech/Roche), which was first approved in...

Mar 6th, 2017 - Imatinib mesylate is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). The indications for imatinib have expanded since its initial approval.